A. M. Haritova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
A. M. Haritova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
L. D. Lashev
Department of Pharmacology, Physiology of Animals and Physiological Chemistry, Faculty of Veterinary Medicine, Trakia University, Stara Zagora, Bulgaria
2 shared publicationsL. Lashev
Trakia University
2 shared publicationsB. I. Gurov
National Diagnostic Scientific Institute of Veterinary Medicine ‘Prof. Georgi Pavlov’, Sofia, Bulgaria
1 shared publicationD. Pashov
Department of Pharmacology, Toxicology and Therapeutics, Faculty of Veterinary Medicine, Trakia University, Student’s Campus, Stara Zagora 6000, Bulgaria
1 shared publicationH. A. Djeneva
Microbiology and Virology, Medical Faculty, Trakia University, Stara Zagora, Bulgaria
1 shared publicationJ. Fink‐Gremmels
Department of Veterinary Pharmacology, Pharmacy and Toxicology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
1 shared publication
Latest Publications
- 9 July 2008
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 31 (4) , 378-385
Expression of MDR1, MRP2 and BCRP mRNA in tissues of turkeys
MDR1, MRP2 and BCRP are members of the superfamily of ABC membrane transporters that export a large variety of structurally diverse substances out of the cell, hence being an integral part of various biological barriers. Here we report for the first time the tissue distribution of these ABC efflux transporters in the gastrointestinal tract (crop, proventriculus, duodenum, proximal and distal jejunum, ileum, caecum, colon) as well as in liver, kidney, lung, brain, adrenal gland, ovaries, oviduct and testes in BUT9 turkeys. MDR1 and BCRP mRNA expression was detected in all tissue samples, and the highest levels were measured in the small intestines. The tissue distribution of MRP2 mRNA was less consistent and some tissues seemed to lack any significant expression. Moreover, in consideration of previous findings suggesting that fluoroquinolones are substrates and modulators of ABC transporters, the effect of orally administered danofloxacin mesylate on the levels of MDR1, MRP2 and BCRP mRNA expression was investigated. Danofloxacin treatment resulted in a significant up‐regulation of the measured transporters at the transcriptional level in the upper part of gastro‐intestinal tract, liver and kidneys as well as in barrier‐protected organs, such as the brain. However, despite this significant increase in the transcription levels, the pharmacokinetic parameters after repeated application of danofloxacin mesylate were not significantly altered.
- 9 July 2008
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 31 (4) , 378-385
Expression of MDR1, MRP2 and BCRP mRNA in tissues of turkeys
MDR1, MRP2 and BCRP are members of the superfamily of ABC membrane transporters that export a large variety of structurally diverse substances out of the cell, hence being an integral part of various biological barriers. Here we report for the first time the tissue distribution of these ABC efflux transporters in the gastrointestinal tract (crop, proventriculus, duodenum, proximal and distal jejunum, ileum, caecum, colon) as well as in liver, kidney, lung, brain, adrenal gland, ovaries, oviduct and testes in BUT9 turkeys. MDR1 and BCRP mRNA expression was detected in all tissue samples, and the highest levels were measured in the small intestines. The tissue distribution of MRP2 mRNA was less consistent and some tissues seemed to lack any significant expression. Moreover, in consideration of previous findings suggesting that fluoroquinolones are substrates and modulators of ABC transporters, the effect of orally administered danofloxacin mesylate on the levels of MDR1, MRP2 and BCRP mRNA expression was investigated. Danofloxacin treatment resulted in a significant up‐regulation of the measured transporters at the transcriptional level in the upper part of gastro‐intestinal tract, liver and kidneys as well as in barrier‐protected organs, such as the brain. However, despite this significant increase in the transcription levels, the pharmacokinetic parameters after repeated application of danofloxacin mesylate were not significantly altered.
- 20 October 2004
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 27 (5) , 381-384
Pharmacokinetics of gentamicin and apramycin in turkeys roosters and hens in the context of pharmacokinetic–pharmacodynamic relationships
- 20 October 2004
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 27 (5) , 381-384
Pharmacokinetics of gentamicin and apramycin in turkeys roosters and hens in the context of pharmacokinetic–pharmacodynamic relationships
- 1 July 2004
- Published by Springer Nature in Veterinary Research Communications
- Vol. 28 (5) , 429-435
Pharmacokinetics of Amikacin in Lactating Sheep
The pharmacokinetics of amikacin (AMK) were investigated after intravenous (i.v.) and intramuscular (i.m.) administration of 7.5 mg/kg bw in 6 healthy lactating sheep. After i.v. AMK injection (as a...
- 1 July 2004
- Published by Springer Nature in Veterinary Research Communications
- Vol. 28 (5) , 429-435
Pharmacokinetics of Amikacin in Lactating Sheep
The pharmacokinetics of amikacin (AMK) were investigated after intravenous (i.v.) and intramuscular (i.m.) administration of 7.5 mg/kg bw in 6 healthy lactating sheep. After i.v. AMK injection (as a...
- 1 June 2003
- Published by Elsevier in Research in Veterinary Science
- Vol. 74 (3) , 241-245
Pharmacokinetics of enrofloxacin in lactating sheep
- 1 June 2003
- Published by Elsevier in Research in Veterinary Science
- Vol. 74 (3) , 241-245
Pharmacokinetics of enrofloxacin in lactating sheep